Corvus Pharmaceuticals (CRVS) Net Income (2015 - 2026)

Corvus Pharmaceuticals' Net Income history runs 12 years deep, the most recent figure standing at -$13.1 million for Q1 2026.

• In Q1 2026, Net Income fell 183.23% year-over-year to -$13.1 million; the TTM figure through Mar 2026 stood at -$42.2 million (down 12.62% YoY), while the FY2025 annual figure was -$13.3 million, up 77.45% from the prior year.
• Net Income was -$13.1 million for Q1 2026 at Corvus Pharmaceuticals, down from -$11.6 million in the prior quarter.
• In the past five years, Net Income ranged from a high of $15.7 million in Q1 2025 to a low of -$39.5 million in Q3 2024.
• Historically, Net Income has averaged -$8.2 million across 5 years, with a median of -$7.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Income plunged 669.91% in 2024, then surged 364.98% in 2025.
• A 5-year view of Net Income shows it stood at -$5.7 million in 2022, then advanced by 7.36% to -$5.2 million in 2023, then sank by 89.35% to -$9.9 million in 2024, then retreated by 16.85% to -$11.6 million in 2025, then fell by 12.73% to -$13.1 million in 2026.
• The last three Net Income figures came in at -$13.1 million (Q1 2026), -$11.6 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.